Endostart Appoints Christopher Rowland Chairman of the Company’s Board of Directors.
15.7.2022 09:00:00 EEST | Business Wire | Press release
The growth of Italian medical device start-up Endostart continues with the appointment of Christopher Rowland, a global expert in the medical device industry, to Chairman of the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220714005706/en/
Endostart is proud to announce the appointment of Chris Rowland as Chairman of the company’s Board of Directors. Chris is a well-known expert in the medical device industry global market and joins Endostart with over 30 years of experience in sales, product development, marketing, business development, and executive leadership in the US and abroad. His unrivalled experience and business competency will be crucial as we commercialize our innovative medical device to improve the colonoscopy experience for physicians, patients, and the entire health care system. (Photo: Business Wire)
With over 30 years of experience in positions of increasing responsibility in sales, product development, marketing, business development, and CEO leadership in the US and abroad, Chris brings an unrivaled experience and competency in a wide variety of clinical and commercial medical devices verticals, including gastroenterology, cardiology, urology, radiology, and peripheral vascular specialties.
His professional experience includes 17 years with Boston Scientific, ending as the Global VP of Marketing for the Endoscopy Division; he also served as President of Given Imaging Inc. (acquired by Covidien/MDT) and President/CEO of Neotract Inc. (acquired by Teleflex). Chris is also currently the President and CEO of Tricol Biomedical, a leader in hemostasis technology.
In his new role, Chris will work with and coordinate the Board of Directors for Endostart.
“With his long history of leadership and his expertise in the digestive endoscopy industry, Chris is the ideal Chairman of the Board for Endostart,” said Alessandro Tozzi, CEO and founder of Endostart. “We are certain that Chris will be a driving force in our success.”
“I am excited to support the investors and the leadership team of this dynamic company. I believe Endostart is poised for significant growth reflecting demand for its innovative products to enhance endoscopic performance,” said Mr. Rowland. “I look forward to helping Endostart maximize shareholder value and realize its commercial potential.”
About Endorail™
The first product from Endostart is Endorail™, an innovative medical device aimed at facilitating completion of colonoscopy procedures using Magnetic Balloon Technology. This technology is designed to enhance endoscope performance and enable endoscopists to easily achieve quality standards. Endorail received a CE mark in 2019 and has been tested in a clinical setting. It is not yet cleared by the US Food and Drug Administration (FDA).
About Endostart
Founded in 2018, Endostart is focused on developing and manufacturing next-generation medical devices for gastrointestinal endoscopy. The company is ISO 13485 certified. It has an international board of directors and a strong medical advisory board. It recently announced a capital increase of €8.2M (USD $10M).
Website: www.endostart.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005706/en/
Contact information
Contact: info@endostart.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lattice to Showcase Industry-Leading FPGA Innovations at FPGA Conference Europe 202616.6.2026 23:00:00 EEST | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA Conference Europe. Lattice will participate in various speaker sessions to showcase how low power FPGAs are driving innovation across multiple sectors. The company will also demonstrate its latest FPGA technology advancements in physical AI, advanced connectivity, security, and more. Who: Lattice Semiconductor What / When (GMT+2): June 30 – July 2: Lattice Presentations & Demo Showcase Speaker sessions: Day 1 – 3 Speaker Sessions: Lattice FPGA deep dive sessions spanning physical AI, advanced connectivity, security, and design tools Date Time Session June 30 9:45 a.m. FPGA Verification and Testing by Arrow 11:15 a.m. Trusted Resilience Edge: Unified FPGA-TPM for Post-Quantum Cryptography RED & Cyber Resilience Act 12 p.m. SIPHashIP for Embedded Security: Enabling RED Compliance and CRA Readiness in Smart AR/VR Systems 2:15 p.m. Foundations of FPGA Security
IQM Deploys Its First U.S. Quantum Computer at Oak Ridge National Laboratory16.6.2026 21:53:00 EEST | Press release
The Department of Energy's Oak Ridge National Laboratory (ORNL) today launched Pathfinder, the first commercially procured quantum computer at ORNL, built and deployed by IQM Quantum Computers. The 20-qubit IQM Radiance system marks IQM's first quantum computer installation in the United States. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616373175/en/ IQM's first U.S. quantum computer is live — at DoE Oak Ridge National Laboratory. The deployment comes ahead of IQM's planned listing on the Nasdaq Global Select Market through its business combination with Real Asset Acquisition Corp. (Nasdaq: RAAQ), expected to close in mid-2026. ORNL is home to Frontier, the world's most powerful supercomputer for open science, and to one of the most consequential high-performance computing environments anywhere. Pathfinder now sits inside that environment, connected to HPC systems in the National Center for Computational Sciences Tec
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology16.6.2026 20:00:00 EEST | Press release
Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, France and the Netherlands, as well as monetary damages and penalties for non-compliance. The court also required Siemens to execute a mandatory recall and destruction of all affected systems in those countries. On June 10, 2026, the UPC determined that Siemens infringed upon European Patent EP 2 352 431, Hologic’s Focusing Technology on the Envision™ Platform, the first FDA-approved mammography innovation of its kind.1 In addition to the broad injunction against Siemens, recall and destruction of infringing systems, Hologic will rec
RealTime Reservation Acquires STAY to Create Leading Global Guest Experience Platform Serving 2,000+ Properties Across 75+ Countries16.6.2026 19:30:00 EEST | Press release
RealTime Reservation (RTR), the industry leader in dynamic hospitality booking technology for onsite activities, amenities, and ancillary revenue management, today announced its acquisition of STAY, creating a global end-to-end guest experience platform for the hospitality industry. The combined company will serve more than 2,000 hospitality properties across 75+ countries throughout North America, Europe, Latin America and the Caribbean. The combination significantly expands RTR's international footprint and strengthens its position as a leading provider of guest engagement, ancillary revenue, and guest experience technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616258776/en/ Pictured: RealTime Reservation's dynamic booking interface allows hotel guests to select and reserve pool and beach amenities by location, date, and availability, streamlining ancillary revenue management for properties of any size. Courte
Happy Holidays S.A. and JTA Investment Holding Announce €65 Million Investment for SARTIMARE Tourism Development in Greece16.6.2026 18:42:00 EEST | Press release
Happy Holidays S.A. today announced the signing of an Investment Agreement with Qatar-based JTA Investment Holding for the development of the sustainable SARTIMARE Beach Resort & Spa project in Sarti, Halkidiki, Greece. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616892834/en/ Dr. Amir Ali Salemi Zadeh, CEO of JTA Investment Holding and Georgios Iosifidis, Founder & Owner of Happy Holidays S.A. Under the agreement, JTA Investment Holding will invest €65 million into the development. The project will be built on a site of approximately 120,900 square meters, with construction scheduled between 2027 and 2030. Designed with a strong commitment to environmental responsibility, the SARTIMARE project will feature luxury hospitality facilities, premium residences and villas, wellness amenities, retail, food & beverage outlets, and marina infrastructure. The project's valuation is expected to exceed €100 million as key develop
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom